<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2014-12-04 10:38:20Immunotherapy Immune system Carcinogenesis Cancer immunotherapy Oncoantigen Medicine Immunology Cancer treatments |
| # 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim WiDocID: 1vdls - View Document |
| Microsoft Word - ST64 Cancer Immunotherapy v1.0.docxDocID: 1uTyz - View Document |
| FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy ProgramDocID: 1tGAn - View Document |
| Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer LabDocID: 1tBVB - View Document |